3.2 based on 26 reviewsView this provider's reviews
Patient satisfaction ratings and reviews are based on personal opinions. Before you choose any doctor you should take into account their background, training, specialized experience AND their patient satisfaction to ensure they are the right fit for you.
We're trying something new with Top Care Areas.Was it helpful for you?YesNo
This content was provided by Dr. Chu "As the senior partner of the largest urology group in Inland Empire, we believe in always doing the right thing for our patients. It is a privilege to have the trust of our patients which we will never violate. As a Christian physician, I believe God is the Great Physician and He works through my hands."
No sanctions history found for the years that Healthgrades collects data.
0 Board Actions
No board actions found for the years that Healthgrades collects data.
Tulane University of Louisiana
Undergraduate School | Graduated 1973
Tulane University School Of Medicine
Medical School | Graduated 1979
University Tex Med Br
Internship Hospital | Completed 1980
Uc Irvine Med Center
Residency Hospital | Completed 1985
University Of Illinois Urbana Champaign
Other Education | Completed 1974
Awards & Recognition
Awards & Honors
Healthgrades Honor Roll
Charles R Ream MD Award 2009 for excellence in Medical Journal Publication, 2009
Media & Publications
Pathophysiology of Overactive Bladder, American Journal of Medicine Supplement, March 2006 Vol. 119 (3A) 3-8, March 2006
Management of Overactive Bladder and Urge Urinary Incontinence in the Elderly Patient., March 2006
A Clinical Study of LA2250 22.5 MG: A New Subcutaneous Depot Delivery System for Luprolide Acetate in the Treatment of Prostate Cancer., Sept. 2002
A Clinical Study of LA 2500 7.5MG: A New Subcutaneous Depot Delivery System for Luprolide Acetate in the Treatment of Prostate Cancer., Nov. 2002
Efficacy and safety of Solifenacin Succinate 10 mg Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controll, Parellel-Group Trial in Patients With Overactive Bladder, 2009:70:
Management of Incontinence for Family Practice Physicians,, March 2006
A Twelve Month Clinical Study of LA-2585 45.0 MG: A New 6-Month, Subcutaneous Delivery System for Leuprolide Acetate for the Treatment of Prostate Cancer., 2006 Feb
A Phase I, multicenter, open-label study of the safety of two doses levels of a human monoclonol antibody to human alphav integrins, intetumumab, in combination with docetaxel and prednisone in patients with castration resistent metastatic prostate cancer, 2011 29:67
Toremifene Improves Lipid Profiles in Men Receiving Androgen Deprivation therapy for Prostate Cancer, Iterim analysis of a Multi-Center Phase III Study, April 2008
An Eight Month Study of LA-2573 30.0g, A new 4 month subcutaneous delivery system for Luprilide Acetate in the treatment of Porsotae., 2003 Aug
Extended-Release Formulations of Oxybutynin and Tolterodine Exhibit Similar Central Nervous System Tolerability Profiles: A Subanalysis of Data From the OPERA Trial., 2005 Jun
A new Prostate Cancer Drug: Eligard, 2000
Memberships & Professional Affiliations
Dr. Chu does not have any memberships or affiliations listed. If you are Dr. Chu and would like to add memberships or affiliations, please update your profile.
We have a tremendous shortage of urologists in the nation. There is an even more acute shortage for urologists in our area due to the unwillingness of the newly trained urologists to come to our city. In order to keep the quality of the new associates we hire, we are unwilling to hire just any urologist. As a result there are times when the wait in our office is very long. We ask for your patience
Are you Dr. Chu?
Make it easy for patients to share their feedback. Also manage your personalized profile!